Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. uri icon

authors

  • Voors, Adriaan A
  • Lanius, Vivian
  • van der Laan, Michael
  • Solomon, Scott D
  • Shah, Sanjiv J
  • Bax, Jeroen J
  • Butler, Javed
  • Gheorghiade, Mihai
  • Hernandez, Adrian F
  • Dalane W Kitzman, MD
  • McMurray, John J V
  • Wirtz, Antonieta Bomfim

publication date

  • January 1, 2018